Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
May 23, 2017
Plazomicin Granted FDA Breakthrough Therapy Designation
May 23, 2017 SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug ...
May 23, 2017
OSE Immunotherapeutics Strengthens R&D Team with Appointment of Two Senior Talented Immunologists
NANTES, France, May 22, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173); (Mnémo:OSE) announced today the appointment of Aurore Morello, Ph.D., as Immunology Researcher, and ...
May 23, 2017
Positive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference
WARREN, N.J., May 22, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced the presentation of new clinical data from a ...
May 23, 2017
Windtree Receives SBIR Grant in Continued Support of AEROSURF® Phase 2b Clinical Trial
WARRINGTON, Pa., May 22, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today ...
May 23, 2017
Positive Phase 2a results with microdoses of dasiglucagon support use in a dual-hormone artificial pancreas system
Copenhagen, May 23, 2017 - Zealand Pharma ("Zealand") announces positive results from a Phase 2a trial following administration of the multiple-dose version of dasiglucagon in adult ...
May 23, 2017
BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED)
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that BioTime, ...
May 23, 2017
Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update
AUSTIN, Texas, May 23, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino ...
May 22, 2017
INNATE PHARMA : IPH4102: Completion of the dose escalation part of the phase I trial - Data to be presented at ICML in June 2017 in Lugano
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced that it has completed the dose escalation part of its ongoing Phase ...
May 22, 2017
Kiadis to Host Key Opinion Leader Meeting on Addressing the Risks of Haloidentical HSCT in Blood Cancer
Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow ...
May 22, 2017
BrainStorm to Present at Cell & Gene Exchange Conference in Washington DC
HACKENSACK, N.J. and PETACH TIKVAH, Israel, May 22, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative ...
May 22, 2017
iCAD to Participate in Two Upcoming Investor Conferences
NASHUA, N.H., May 22, 2017 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the ...
May 22, 2017
Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry
EMERYVILLE, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system ...
May 22, 2017
Rockwell Medical Issues Letter to Shareholders Explaining Why Electing Mark Ravich Could Do Lasting Harm
WIXOM, Mich., May 22, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI) today mailed a letter to its shareholders in connection with the Company’s upcoming ...
May 22, 2017
Onconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association
NEWTOWN, Pa., May 22, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to ...
May 21, 2017
Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine
SAN DIEGO--(BUSINESS WIRE) -- La Jolla Pharmaceutical Company (LJPC) (La Jolla) today announced that results of the ATHOS-3 (Angiotensin II for the Treatment of High-Output ...
May 19, 2017
OSE Immunotherapeutics to Present at Annual Sachs Immuno-Oncology: BD&L and Investment Forum
NANTES, France, May 18, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA(ISIN:FR0012127173) (Mnémo:OSE) announced today that the Company will present at the upcoming “Annual Sachs Immuno-Oncology: ...
May 19, 2017
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results
VANCOUVER, British Columbia and MENLO PARK, Calif., May 18, 2017 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the ...
May 19, 2017
Santhera Provides Update on Timeline for Application of Raxone® in Duchenne Muscular Dystrophy in Europe
Liestal, Switzerland, May 19, 2017 - Santhera Pharmaceuticals, a specialty pharmaceutical company focused on the development of innovative treatments for rare mitochondrial and neuromuscular diseases, announces ...
May 18, 2017
Why won’t VCs return your calls and emails?
You have this breakthrough invention. You know it will change the world. But passion alone isn’t enough. You need moolah to fuel your innovations. And ...
May 18, 2017
Arena Pharmaceuticals to Host Key Opinion Leader Event on Pulmonary Arterial Hypertension (PAH) on May 25 in New York City
SAN DIEGO, May 18, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA), today announced that it will host a key opinion leader (KOL) event for investors focused ...
Page 110 of 117